Stemline Therapeutics (STML) Upgraded by BidaskClub to “Hold”

Share on StockTwits

Stemline Therapeutics (NASDAQ:STML) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

A number of other research firms have also commented on STML. Zacks Investment Research upgraded shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 22nd. HC Wainwright restated a “buy” rating on shares of Stemline Therapeutics in a research note on Monday, June 18th. ValuEngine lowered shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, July 16th. Cowen restated a “buy” rating on shares of Stemline Therapeutics in a research note on Friday, June 15th. Finally, Roth Capital started coverage on shares of Stemline Therapeutics in a research note on Tuesday, June 12th. They issued a “buy” rating and a $30.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Stemline Therapeutics currently has an average rating of “Buy” and an average target price of $30.00.

Shares of NASDAQ:STML opened at $15.15 on Tuesday. Stemline Therapeutics has a 12 month low of $7.30 and a 12 month high of $20.55. The firm has a market cap of $452.60 million, a P/E ratio of -5.15 and a beta of 0.05.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.02). The company had revenue of $0.50 million for the quarter. analysts predict that Stemline Therapeutics will post -2.73 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlueMountain Capital Management LLC acquired a new position in Stemline Therapeutics in the second quarter valued at $137,000. State Board of Administration of Florida Retirement System acquired a new position in Stemline Therapeutics in the second quarter valued at $166,000. Two Sigma Investments LP acquired a new position in Stemline Therapeutics in the fourth quarter valued at $170,000. MetLife Investment Advisors LLC acquired a new position in Stemline Therapeutics in the fourth quarter valued at $186,000. Finally, Sofinnova Ventures Inc purchased a new stake in shares of Stemline Therapeutics in the first quarter valued at about $193,000. Institutional investors own 67.22% of the company’s stock.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Featured Story: What is a Leveraged Buyout (LBO)?

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

ExlService Holdings, Inc.  CEO Rohit Kapoor Sells 6,400 Shares
ExlService Holdings, Inc. CEO Rohit Kapoor Sells 6,400 Shares
Jazz Pharmaceuticals PLC  CEO Bruce C. Cozadd Sells 1,300 Shares
Jazz Pharmaceuticals PLC CEO Bruce C. Cozadd Sells 1,300 Shares
Zacks: Brokerages Expect WSFS Financial Co.  Will Announce Earnings of $0.87 Per Share
Zacks: Brokerages Expect WSFS Financial Co. Will Announce Earnings of $0.87 Per Share
VersaBank  Director Patrick George Acquires 111,800 Shares of Stock
VersaBank Director Patrick George Acquires 111,800 Shares of Stock
CanWel Building Materials Group Ltd  Director Marc Seguin Acquires 10,000 Shares of Stock
CanWel Building Materials Group Ltd Director Marc Seguin Acquires 10,000 Shares of Stock
Bayerische Motoren Werke  Given a €100.00 Price Target at Jefferies Financial Group
Bayerische Motoren Werke Given a €100.00 Price Target at Jefferies Financial Group


Leave a Reply

 
© 2006-2018 Zolmax.